George Jeffrey P. 4
4 · LENZ Therapeutics, Inc. · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
LENZ Therapeutics Director George Jeffrey P. Buys 5,592 Shares
What Happened
George Jeffrey P., a director of LENZ Therapeutics, reported a purchase of 5,592 company shares on 2026-03-27. The filing shows a weighted-average price of $8.92 per share for an aggregate cost of $49,890. The transaction is coded "P" (purchase) and is described as an open market or private purchase.
Key Details
- Transaction date: 2026-03-27; Form 4 filed: 2026-03-30 (timely filed).
- Shares acquired: 5,592 at a weighted average price of $8.92; total ≈ $49,890.
- Price range reported (footnote): $8.80 to $9.12; the reporter will provide per-price breakdown on request (Footnote F1).
- Shares owned after the transaction: not specified in the provided filing details.
- Transaction code: P = Purchase (open market/private purchase). No 10b5-1 plan, tax withholding, or gift indicated in this filing.
Context
Insider purchases are often watched by investors as potentially positive signals, but the filing does not state the reporting person's motive. This was a direct equity purchase (not an option exercise or restricted award) and the Form 4 was filed within the standard reporting window.
Insider Transaction Report
Form 4
George Jeffrey P.
Director
Transactions
- Purchase
Common Stock
[F1]2026-03-27$8.92/sh+5,592$49,890→ 5,592 total
Footnotes (1)
- [F1]Represents the weighted average share price of an aggregate total of 5,592 shares purchased in the price range of $8.80 to $9.12 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Signature
/s/ Daniel R. Chevallard, as Attorney-in-Fact|2026-03-30